Daratumumab Effective in Advanced Multiple Myeloma


The targeted agent, daratumumab, which is still in clinical trials, appears to be effective in patients with multiple myeloma that has stopped responding to standard therapies. These results were recently published in the New England Journal of Medicine.

Multiple myeloma is a cancer that originates in specific blood cells called plasma cells. Ultimately, cancerous plasma cells start to crowd bone marrow, lymph nodes and spleen; decrease the effectiveness of other blood cells, and invade other organs.

There are several treatment options for multiple myeloma; however, once the cancer stops responding to standard therapies, it is referred to as refractory and therapeutic options at that point in the disease remain scarce.

Multiple myeloma cells overexpress the protein called CD38. Therefore, researchers have designed daratumumab to specifically target and bind to CD38. Daratumumab binds to the cancer cells, and through multiple pathways, the cancer cells are killed once the binding occurs.

The recent trial evaluating daratumumab included patients with multiple myeloma that had stopped responding to a median of 4 prior therapies. This was an early-phase trial evaluating daratumumab, so patients were treated with 2 different doses of the agent.

Among patients treated at the higher dose, 36% achieved a disease response.

Among responders, 65% of patients did not experience disease progression at one year following therapy.

Daratumumab was well tolerated, particularly considering this group of patients had received extensive prior therapy.

Reference: Lokhohrst H, Plesner T, Laubach J, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. New England Journal of Medicine. 2015; August 26, 2015DOI: 10.1056/NEJMoa1506348.